The sentence that stays with you is five words long: "we would live here for trials." It appears, unattributed, in the free-text comments of an online survey of people with corticobasal syndrome, the rare tau-associated disease that stiffens one side of the body, steals the use of a hand, and takes speech and thinking with it. Someone typed that into a box. Someone else typed "whatever is needed." Those two fragments are now part of the small published record of what this population will tolerate, and they read less like enthusiasm than like arithmetic done by people who know how little time is on the table.
The numbers around them come from Rebecca Snell, Brad Boeve, Howard Rosen, Hilary Heuer, Adam Boxer and Lawren VandeVrede, published on 26 December 2025 as a conference abstract in Alzheimer's & Dementia. The survey ran online from February 2015 to November 2020 among people already enrolled in ARTFL, the multisite North American observational study of frontotemporal lobar degeneration. Sixty-six respondents had corticobasal syndrome as a primary or secondary phenotype, as judged by a study clinician. Sixty-two percent of the surveys were filled in by the patient; 38 percent by a caregiver or family member, which is itself a fact about this disease. Ninety-one percent asked to be contacted about clinical trials. Of the six who declined, two commented that the severity of their illness ruled participation out.
Then the ladder of burden. Ninety-seven percent said they would come in once a year. Eighty-eight percent would come quarterly. Sixty-six percent would come every month. Forty-three percent would come every week, and 17 percent would come more often than that. Two people said they could not travel at all because of how far the disease had progressed. On the shape of the visit rather than its frequency: full-day evaluations were acceptable to 91 percent, 9 percent preferred a half day or less, and 65 percent said they would do multi-day assessments spread across a week. This is a survey of stated willingness, not a record of what anyone actually did, and it is preliminary work reported in abstract form rather than a peer-reviewed paper.
What gives the finding its edge is the second half of the picture. The same UCSF group notes, in a separate December 2025 abstract, that only a handful of clinical trials have ever been run in corticobasal syndrome at all. Their proposed answer is deliberately small: a phase 1b/2a, six-month, randomized, double-blind, placebo-controlled study of a tau-directed therapeutic in 24 people with CBS, stratified by a plasma p-tau217 blood test into the 4R-tauopathy and Alzheimer's-type tau groups, randomized two to one, run at a single site with an expected 2025 launch and a six-month open-label extension. Twenty-four people. Against 66 who, five to ten years earlier, had already said they would come weekly.
For a family sitting with a CBS diagnosis, the practical meaning is narrow and worth stating plainly. This survey does not put a treatment within reach, and nothing in it should change what anyone does about their own care. What it does is remove one excuse from the design conversation. When trialists argue that a schedule is too punishing for a population this frail, or that lumbar punctures and full-day batteries and monthly travel will sink recruitment, there is now at least one published dataset pointing the other way, gathered from the people themselves and from the relatives who answered on their behalf. The limiting factor described in this cohort was not reluctance. It was the disease arriving first: the two who could not travel, the two decliners who said severity had settled it.
The caveats are real and the authors do not hide them. These 66 were already research volunteers in a consortium study, which is close to the definition of a self-selected group, and willingness typed into a survey box is a cheaper promise than a Tuesday morning drive across a state line for the fourteenth time. The responses are also old, collected up to five years before the p-tau217 blood tests that now allow CBS to be split by underlying tau type. But nobody else has asked this question of this population, and until somebody does, this is the number that stands.